Only 40% of Australians want the AstraZeneca vaccine. What could this mean for CSL (ASX:CSL)?

Only 40% of Australians are willing to have the AstraZeneca vaccine. What, if anything, could this mean for CSL Limited (ASX: CSL)?

| More on:
People marching and holding up anti covid vaccine signs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New data reveals that only 40% of Australians are willing to take the AstraZeneca plc (LSE: AZN) COVID-19 vaccine. What, if anything, could this mean for CSL Limited (ASX: CSL)?. The data, released Monday in an Essential Research poll, comes at an inopportune time for the country as a whole, with the inoculation roll-out already delayed.

With CSL being the main manufacturer and distributor of the AstraZeneca vaccine in Australia, it would be interesting to know what the company makes of the latest figures.

Let's take a closer look at the data.

1 in 5 Australian women refuse to get vaccinated

Since Essential's previous poll, which was taken before news surrounding possible blood clotting side-effects in those under 50 surfaced, the number of people saying they would refuse to get vaccinated increased from 12% to 16%. This includes 20% of all women and 23% of all 18 to 34-year-olds. The 16% figure is still within tolerable levels to achieve herd immunity, it should be noted.

42% of respondents said they want to get vaccinated as soon as possible, while another 42% said they would prefer to wait for a time before receiving their vaccination.

The number who said they would be willing to have any vaccination is 37%. A further 3% said they would have the AstraZeneca vaccine but not the Pfizer Inc (NYSE: PFE) vaccine. Perhaps most concerning is the number of those people aged over 50 who said they would rather have the Pfizer vaccine than the AstraZeneca one.

As mentioned, those under 50 are not recommended to have the AstraZeneca vaccine. The government is also mandating that those over 50 should not be given the Pfizer vaccine if the AstraZeneca one is available. Nearly a third of respondents aged between 50 and 69 said they want the Pfizer injection, as well as 16% of those aged 70+. Men are much more likely than women to accept either vaccine (48% to 27% respectively).

What could this mean for CSL?

As no Australian consumers can buy vaccines directly (they are purchased by the Commonwealth to then be distributed to states, GPs, and other providers) it's possible CSL may not be greatly impacted by any hesitancy among Australians over the AstraZeneca vaccine. Furthermore, according to JP Morgan healthcare analyst David Low, as reported by The Sydney Morning Herald earlier this year:

CSL's exposure to vaccines is quite small especially after the University of Queensland vaccine program was terminated. It's about the relative financial contribution – the potential earnings from COVID vaccines is modest compared with the group's other business lines.

On the other hand, the government has already responded to public sentiment and changing health advice by recommending against those under 50 having the AstraZeneca vaccine. Motley Fool Australia has contacted CSL for comment.

CSL share price snapshot

Over the last 12 months, the CSL share price has decreased by around 12%. Shares in the company fell from $285.00 each at the beginning of the year to a 52-week low of $242.00 in early March. Since then, the CSL share price has partially recovered to its current level of $273.49. However, the company's shares are still trading almost 15% lower than their 52-week high of $320.42 reached in November.

CSL has a market capitalisation of $124.5 billion.

Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Is this a new threat for CSL shares?

There's a new wonder drug on the scene. Should shareholders be concerned?

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Earnings Results

What's with the Neuren Pharmaceuticals share price today?

The full market reaction to the Daybue developer's FY23 earnings report won't be seen until tomorrow.

Read more »

private health insurance diagram.
Healthcare Shares

What's going on with the Medibank share price today?

Shareholders will be happy to see Medibank shares drop in value today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Mesoblast share price tumbles on US$32.5m half-year loss

This biotech continues to burn cash.

Read more »

Health professional working on his laptop.
Healthcare Shares

Ramsay Health Care share price falls on profit crunch and dividend cut

This private hospital operator continues to battle with higher costs.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Guess which ASX pharmaceuticals stock is up 400% in 2 days

Big returns have been generated from this pharma stock this week.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is this ASX 200 pharmaceuticals stock crashing 15% today?

Investors haven't responded positively to a sales update.

Read more »

A little girl with red hair runs excitedly with a rocket strapped to her back, trying to launch.
Share Gainers

This small-cap ASX stock just rocketed 39%. What's doing?

A stock no one has heard of is lighting up trading screens on Wednesday. You might hear this name more…

Read more »